US FDA Authorizes Pfizer's Paxlovid, In The Nick Of Time
The US FDA’s Christmas gift was the authorization of the first oral pill for treatment of mild-to-moderate COVID-19; Pfizer expects to have 30 million doses of Paxlovid available by mid-2022.
You may also be interested in...
The company announced updated results from a standard-risk study, which it will include in its overall new drug application, but whether Paxlovid will see approval or uptake in that group is another question.
Senior Pfizer executive outlines the accelerated development approach for Paxlovid, one that took just 17 months, but was done without cutting any corners for safety and also sought to guard against resistance from the design perspective.
The company could reach $100bn in revenues in 2022 for the first time, powered by Comirnaty and Paxlovid; actual sales for the COVID-19 products are likely to go higher based on supply contracts.